HOXB9 and melanoma: In the GSE91061 melanoma cohort [34], the relationship between HOXB9 expression and response to anti-PD-1 therapy in melanoma patients suggests that individuals with low HOXB9 expression had better survival rates and longer survival times compared to those with high HOXB9 expression (Figure 8D).